---
title: "LSPG plans to increase its investment in its holding subsidiary WanNianQing Pharmaceutical by 22.8 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/226331829.md"
description: "LSPG plans to increase its investment in its holding subsidiary WanNianQing Pharmaceutical by 22.8 million yuan. After the capital increase, the registered capital of WanNianQing Pharmaceutical will rise to 32 million yuan, and the shareholding ratio will increase from 85% to 92.50%. Minority shareholder Yan Wenmeng will increase his investment by 1.2 million yuan, maintaining a 5% shareholding; Lei Yihang will waive his preemptive subscription rights, reducing his shareholding ratio to 2.50%. This capital increase aligns with the company's strategic layout and will help enhance the operational capabilities of the holding subsidiary, promoting the company's long-term development"
datetime: "2025-01-27T07:58:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/226331829.md)
  - [en](https://longbridge.com/en/news/226331829.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/226331829.md)
---

# LSPG plans to increase its investment in its holding subsidiary WanNianQing Pharmaceutical by 22.8 million yuan

According to the announcement from Zhitong Finance APP, LSPG (301111.SZ) announced that its controlling subsidiary, Guangdong LSPG Pharmaceutical Co., Ltd. (hereinafter referred to as "LSPG Pharmaceutical"), intends to increase its registered capital by 24 million yuan based on business development needs. After the capital increase is completed, the registered capital of LSPG Pharmaceutical will change to 32 million yuan. The company plans to increase its investment in LSPG Pharmaceutical by 22.8 million yuan using its own funds, raising its equity stake in LSPG Pharmaceutical from 85% to 92.50%. LSPG Pharmaceutical's minority shareholder Yan Wenmeng intends to increase his investment in LSPG Pharmaceutical by 1.2 million yuan, maintaining his equity stake at 5%. LSPG Pharmaceutical's minority shareholder Lei Yihang has waived his preemptive subscription rights for this capital increase, reducing his equity stake in LSPG Pharmaceutical from 10.00% to 2.50%.

This capital increase aligns with the company's current strategic layout and business development needs, which is beneficial for enhancing the operational capabilities of the controlling subsidiary and promoting the company's long-term operational development

### Related Stocks

- [301111.CN](https://longbridge.com/en/quote/301111.CN.md)
- [000789.CN](https://longbridge.com/en/quote/000789.CN.md)

## Related News & Research

- [Scott Bessent Says Treasury Is 'Moving Quickly' on Stablecoin Rules: What's in the Proposal?](https://longbridge.com/en/news/296133530.md)
- [Exclusive: Marjorie Taylor Greene Warns Social Security Will Go ‘Bankrupt’—But Wall Street CIO Backs Scott Bessent Amid 30-Year Yield Surge](https://longbridge.com/en/news/296329487.md)
- [09:03 ETThe Princeton Review's "Best Colleges for 2027" Rankings Are Out](https://longbridge.com/en/news/296233129.md)
- [09:56 ETParkinson's Foundation Invests More Than $7.5 Million in Research Grants](https://longbridge.com/en/news/296239828.md)
- [12:15 ETInventHelp Inventor Develops Device to Dispense Medication & Access Medical Records (TRO-1648)](https://longbridge.com/en/news/296129516.md)